Received: 15 June 2020
Accepted: 16 June 2020
First Online: 31 July 2020
Ethics approval and consent to participate
: On 20<sup>th</sup> April 2020 this trial received the approval of the Ethics Committee (EC) of Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani-IRCCS, which is the national EC for COVID-19 trials. Informed consent will be obtained from participants prior to involvement in the trial. Given the extraordinary nature of the pandemic diffusion of COVID-19 and the safety measures set up to contain the spread of infection, it is not feasible to provide information to potentially eligible subjects through a face-to-face interview or to obtain informed consent signed in person by the subjects.Therefore, subjects will receive detailed information through a telephonic interview with a suitably qualified and experienced study physician and will then provide their consent through a web-based application. Written information about the study and informed consent forms will be made available through the study website. Whenever possible, a signed informed consent form will be obtained from subjects.Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy is the sponsor of this study.
: Not applicable.
: The authors declare that they have no competing interests.